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The world pharmaceutical industry has been changing profoundly in the last 
decade. Intensive globalization, increased competitiveness and the fight for global 
market shares create new challenges for pharmaceutical companies. Fast 
globalization definitively reinforces the consolidation of the world pharmaceutical 
industry. Alliancing in forms of mergers and acquisitions prevail more and more 
as a strategic orientation for the world pharmaceutical companies. By alliancing, 
they tend to create strategic synergies in an endeavour to be successful, 
competitive and capable to continue with further development circles. The 
pharmaceutical industry in Eastern Europe has been, to a great majority, taken-
over by their multi-national peer companies, thus creating completely new 
managerial challenges. One may forecast that intensive alliancing processes in the 
world pharmaceutical industry are to continue to form even bigger 
pharmaceutical concerns and speed up the oligopolization of the global 
pharmaceutical industry. It can be concluded that strategic management with a 
dedicated market focus is to play an even more important and especially the 
highest top priority function in future globalization and consolidation processes of 
the world pharmaceutical industry. 
 
1. CHARACTERISTICS OF THE WORLD PHARMACEUTICAL 
INDUSTRY  
 
One may define the main characteristics of the world pharmaceutical 
industry as follows:  
 
• increased globalization, 
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• changing structure of competition and increased competitiveness, 
• lack of new products, despite increased investments into R&D 
(Research & Development) activities, 
• fast consolidation and concentration of the world pharmaceutical 
industry, 
• increased importance of strategic management, 
• development of new therapeutic fields and technologies 
(biotechnology, pharmacogenomics), 
• ageing of world population and opening up of new, not yet 
satisfactorily covered therapeutic fields,    
• quick development of the world generic markets. 
 
The world pharmaceutical market has undergone fast, unprecedented, 
tremendous and complex changes in the last several years. The pharmaceutical 
industry is today still one of the most inventive, innovative and lucrative of the 
so-called »high-tech« industries; however, we may say that the pharmaceutical 
industry has been adapting itself more and more to strategic market trends and 
market demands. Further strategic development of the world pharmaceutical 
industry shows clearly its consolidation, concentration and strong market 
orientation. The pharmaceutical industry today, with no doubt, unites one of the 
biggest potentials of all mankind. Development of a brand new drug is 
estimated to need an investment of more than $1.2 billion and takes more than 
12 years to bring it as a finished, legally registered and approved product to the 
market place (Pharma Strategy Group, 2005). This is, at the same time, a very 
complex, comprehensive and highly risky job with no final guarantee that the 
potential new product might succeed on the market and bring back revenues.  
 
If a pharmaceutical company wants to achieve market success with a brand 
new product, it needs to invest strongly into marketing and sales activities. 
Thus, by no surprise, we may conclude that basic research and development 
(R&D), together with marketing and sales activities are two of the most 
important operative and even more strategic priorities of the world 
pharmaceutical industry. Here, the biggest investments of the pharmaceutical 
industry are put by all means. Having analysed these figures, we have found 
that the biggest, inventive world pharmaceutical companies invest, on average, 
approximately 16% of their sales into R&D and even more, about 26% or more 
into marketing and sales activities (Kesič, 2006). However, these ratios, 
especially the one of R&D investment, are even higher with the specialists, like 
biotechnology and pharmacogenomic companies, and much lower with the 
generic pharmaceutical companies (Kesič, 2006). As mentioned, the world 
pharmaceutical industry is structurally not unique, as pharmaceutical companies 
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differ according to their basic mission, performance and strategic development. 
We can define three different groups of the world pharmaceutical companies: 
pharmaceutical companies which primarily work on basic research, 
development and marketing and sales of brand new, inventive, original 
pharmaceutical products (called originators); pharmaceutical companies which 
primarily work on development and sales of generic products (called generic 
producers); and pharmaceutical companies which primarily work on basic 
research and development of biotechnology and pharmacogenomic products 
and technologies of new delivery systems (called specialists). 
 
We need to shortly illustrate the size of the world pharmaceutical market. 
The world pharmaceutical market has been growing steadily in the last years. In 
2005, it posted total sales of $602 billion and a growth rate of 10%. The fastest 
growing world markets and regions are the markets of China, Central and 
Eastern Europe (Russia, Poland, Romania) and certain markets of Latin 
America (Brazil, Mexico, Chile). Nevertheless, it is estimated that the world 
pharmaceutical market will grow by an average of 7% CAGR (Compounded 
Annual Growth Rate) till the year 2010 (Pharma Strategy Group, 2005). 
However, it is estimated that, due to several factors – the expiration of patent 
protection of some of the best sold pharmaceutical products in the most 
developed world markets (major impact is in the USA), worldwide healthcare 
cost reduction and restructuring, ageing of the population and price pressures – 
the world generic markets tend to grow even faster by an average of 12% 
CAGR till the year 2010 (World Review, 2005, Pharma Strategy Group, 2005). 
 
Table 1. World pharmaceutical market 2000-2005 
 
Year Value in billion $ Growth in % 
2000 358  
2001 387 8.1 
2002 422 9 
2003 490 16.1 
2004 547 11.6 
2005 602 10 
 
Source: World Review 2005. 
 
The leading world pharmaceutical markets in terms of sales and also of per 
capita consumption of medicines are the USA, Japan and Germany. The size of 
the American pharmaceutical market comprised more than 40% of the whole 
world pharmaceutical market in 2005. The leading world pharmaceutical 
market has some specific factors which distinguish it from the other world 
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markets like: generally free pricing policy of medicines which is not a common 
issue with other markets (they have usually regulated reference pricing systems, 
especially in the EU); high consumption of medicines; intensive marketing 
activities, sometimes called »turbo marketing«; and intensive competition. 
 
Table 2. Leading world pharmaceutical markets in 2005 
 
Position Markets Value in billion $ 
1. USA 248 
2. Japan 67 
3. Germany 29 
4. France 26 
5. United Kingdom 17 
6. Italy 16 
7. Canada 14 
8. Spain 12 
9. Brazil 9 
10. Mexico 8 
 
Source: own estimation, according to World Review 2005 
 
The products themselves are the main generator of growth of the world 
pharmaceutical industry. Pharmaceutical companies compete on products' 
characteristics and tend to invest heavily into marketing activities in an 
endeavour to gain physicians'/patients' loyalty and, moreover, to compete 
directly with other pharmaceutical companies. According to this, it is no 
surprise that the biggest world multinational pharmaceutical companies invest 
more than 25% of their sales into marketing and sales activities in a goal to get 
considerable global market shares. 
 
For a better understanding, one may define the generic product as a 
bioequivalent product with the same active ingredient as an inventive, original 
one and is subject to standard registration procedure as the original one, 
nevertheless is only legally allowed to be launched upon final expiration of all 
pending intellectual property rights (patent expiry). According to this fact, and 
taking into account that the generic producers do not need to invest huge sums 
of money into basic R&D activities, they merely compete, straightly said, only 
on the lower prices of their products. Development of particular world generic 
markets is in strong connection with existing legislation which may favor or not 
the development and growth of a generic market. The most developed and the 
biggest world generic market in terms of sales is the generic market of the USA 
which has reached close to $40 billion in sales in 2005 and posted a growth rate 
of 12%, which is even higher than the growth rate of the whole pharmaceutical 
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market of the USA, which grew by 7.5% in the same year (World Review, 
2005). 
 






Company Country of origin Sales in billion $ 
World 
market 
share in % 
1. Pfizer USA 44.3 7.4 
2. Sanofi-Aventis France 33.6 5.6 
3. GlaxoSmithKline United   Kingdom 32.1 5.3 
4. Novartis Switzerland 24.9 4.1 
5. AstraZeneca United Kingdom 23.9 4.0 
6. Johnson&Johnson USA 22.3 3.7 
7. Merck&Co USA 22.1 3.7 
8. Roche Switzerland 21.5 3.6 
9. Wyeth USA 15.3 2.5 
10. BMS USA 15.3 2.5 
Source: own estimation, according to official companies’ data 
 
The leading ten world pharmaceutical companies currently command more 
than 42% of the market share of the global pharmaceutical market. For 
comparison reference, this figure was only 30% 10 years ago (Pharma Strategy 
Group, 2005). This is a clear sign and proof how an intensive market 
consolidation and concentration of the pharmaceutical industry has changed the 
world pharmaceutical market in the last several years.  
 
Table 4. Leading world generic companies in 2005 (generics) 
 
Position Company Sales in billion $ 
1. Teva, Israel 5.3 
2. Sandoz, Germany 4.7 
3. Merck Generics, Germany 2.3 
4. Ivax, USA 1.8 
5. Ratiopharm, Germany 1.7 
6. Watson, USA 1.65 
 
Source: own estimation, according to official companies’ data. 
 
The world pharmaceutical industry has undergone deep changes in the last 
decade. Most notably, the strong process of consolidation and concentration has 
been going on practically in all three defined sectors; numerous mergers and 
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acquisitions have occurred, resulting in the complete new alliances and 
companies, respectively. 
 
By comparing the sales figures achieved between originator 
pharmaceutical companies and generic companies (see Tables 3 and 4), we can 
see that originators achieve almost 10 times higher sales than generics. This is 
primarily due to the differences in their strategic orientations: originators invest 
heavily into R&D and marketing and sales activities to get inventive products 
which are marketed at premium prices. However, generics tend to perform a 
typical “follower strategy”, bringing the equivalents of the original products to 
the markets which are priced much lower than the original ones, thus enabling 
the world customers to afford less expensive medical treatments and creating 
additional competition as well.      
 
We may argue that competitiveness has been increasing tremendously, thus 
there is an urgent need for the pharmaceutical companies to behave in a good, 
sharp and speedy manner. We may forecast that, taking into account the 
described elements, a further consolidation and concentration of the world 
pharmaceutical industry is realistically forecasted. We may expect the formation 
of even bigger pharmaceutical concerns in all three sectors of the 
pharmaceutical industry. Besides, further lack of new products is expected with 
highly increased competitiveness and a furious fight for market shares and 
global customers' loyalty.  
 
2. GLOBALIZATION TRENDS 
 
We may say that globalization is almost a synonym for a modern economy. 
Globalization could not be possible without fast and profound technological 
achievements and changes. Nowadays, global competition is mostly based on 
knowledge and technology and the ability to serve customers fast and 
repeatedly. Knowledge, people and markets become more and more basic and 
the most important competition factors among companies and countries, too. 
Globalization has become almost a synonym for economic liberalization and 
foremost opening of world economies. Often, the globalization content is 
interchanged with internationalization or the liberalization of modern 
international economic cooperation. The most active subjects of the 
globalization process are multinational companies. Due to their influence, less 
and less of international trade can be actually described in terms of ‘free trade’, 
as most of is performed among the subsidiaries of multinational companies and, 
thus, being managed and controlled.  
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All this changes the structure of the world market, which has almost 
become predominantly oligopolistic. However, alongside the market, 
competition has changed as well. We may talk about the competitive 
advantages of particular companies. The previous meaning of 
internationalization has been replaced by a globalization domain and the 
previous meaning of the world economy has been replaced by a global 
economy. OECD defines globalization as the “spreading and deepening of 
companies' performance with the target to produce and sell goods or services 
on multiple markets” (OECD, 1993). A later definition of globalization from 
OECD (1994) implies that it is “a developing pattern of international business 
cooperation, which includes investments, trade and contractual ways of 
cooperation, and targets the development of products, production, procurement 
and marketing. Such kind of international performance enables the companies 
to conquer new markets, use their technological and organizational advantages 
and to lower the costs and risks”. Globalization is, thus, strongly related with 
an increased mobility and competition. The main drivers of globalization are 
definitive transnational or multinational companies.  
 
One may assess the following characteristics as significant for their 
performance, especially taking into consideration the multinational 
pharmaceutical companies: 
 
• multinational companies have a strong market position on the most 
important and strategic world markets, 
• they globally integrate and connect their business performance, so 
national identity is no longer important, 
• they perform flexible purchasing strategy, 
• they have a global structure of production, 
• they have a global organization of research and development activities, 
• they have a global marketing organization which supports the strong 
market orientation and the strategic focus to customers. 
 
We may even emphasize that globalization is in its core meaning a 
complex, market conditioned process, which is related and driven by the 
elements of a dedicated and targeted market, performing fast changes and ever-
changing ways of doing business, alongside an ever-increasing competition and 
competitiveness, in a strive to optimally identify the changing needs of the 
world customers and the ability to satisfy their long-term needs. We may 
emphasize the customers should be treated as the most precious value of a 
company. This is why we point out that globalization is a market driven 
process. Thus, it is the core in the process of globalization to be fast, to be 
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market oriented, to have customers, to be innovative, to build knowledge, to 
learn fast and to have proper information. Bartlett and Ghosal (1989) underlined  
that “successful companies of today and tomorrow are these who would be able 
at the same time to satisfy local market needs, to increase global successfulness, 
to strive for constant innovativeness and to constant global learning”.   
 
Peter Drucker (1992) mentioned that “the most important elements of 
development which would influence greatly the strategies, structure and 
performance of the future companies: 
 
• economic relations would be performed in the direction among trade 
blocs instead of countries, 
• business performance would be more and more matter of strategic 
alliancing, which would be integrated into a world economy, 
• restructuring of business would be intensifying and more globalizing, it 
would be important to have information and knowledge, 
• strategic management of companies would be decisive for a 
competitive success, 
• intensive market orientation of companies would be a core advantage 
for achieving a competitive advantage over competitors”. 
 
Svetličič (1996) defined globalization as the 
 
• “multidimensional process, which includes economic, political, legal 
and cultural contents, which together create new quality, 
• globalization means global internationalisation or at least 
internationalisation of activities such as trade, foreign direct 
investments (FDI), contractual ways of international economic 
cooperation in the most important markets, 
• globalization supports common alliancing, which needs global 
coordination and integration of activities in the brand new manner, 
• globalization means production of the same products for a domestic 
consumption and foreign markets as well,  
• globalization means a higher share of components from foreign 
suppliers in the products for domestic consumption and for the export 
as well”.    
 
Globalization is a non-return process and without an intensive 
internationalization, the performance of companies in a modern world would 
not progress. Knowledge and learning are, by no doubt, extremely important 
factors in the process of globalization. Bartlett and Ghosal underlined (1989) 
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that “successful companies of today and tomorrow are those ones who are 
capable to satisfy local needs, increase global effectiveness and strive for 
constant innovativeness and global learning at the same time”. We may say as 
well that the most important size of competitiveness is entrepreneur 
innovativeness, capability to create new products and technologies and to 
understand and perform strategic management activities with a properly 
dedicated market focus. 
 
3. GLOBALIZATION IN THE PHARMACEUTICAL INDUSTRY 
 
The world pharmaceutical industry has been in the intensive processes of 
concentration and consolidation for a period of more than 15 years. As we argue 
that research and development and marketing and sales activities are two of the 
most important and strategic priorities of modern pharmaceutical companies 
and into which the greatest part of funds are being invested as well, we may say 
that the main and strategic reasons, according to our evaluation, for the 
processes of consolidation of the world pharmaceutical industry, are the 
following: 
 
• lack of new products to drive sales growth, 
• fast processes of globalization of the world economy, 
• huge investments needed for R&D, 
• global marketing and sales activities which need large investments as 
well, 
• increased competitiveness, 
• changed structure of the competition, 
• world reforms of the health care systems, 
• increased importance of regulatory issues (registrations, intellectual 
property, litigations). 
 
According to our study and findings, there have been more than 10,000 
alliancing processes in the last decade in the world pharmaceutical industry 
(Datamonitor, 2005). We have found that the consolidation and alliancing 
processes have been carried out practically in all three segments of the world 
pharmaceutical industry (inventive - original pharmaceutical companies, generic 
producers and specialists). The alliancing process has practically created brand 
new pharmaceutical players. Nevertheless, some previously well-known players 
have disappeared from the global market scene. For example, the world leading 
pharmaceutical company Pfizer has been created from five big international 
players like Pfizer itself, Warner Lambert, Upjohn, Searle and Pharmacia, 
respectively. The world leading generic player, Teva from Israel, has acquired 
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more than 10 generic companies, like Lemmon, Gry, Prosintex, Biogal, Human, 
Biocraft, Pharmascience, Copley, Novofarm, Bayer Classics, Sicor and Ivax to 
form today's Teva. Recently, the generic major Barr Pharmaceuticals of the 
USA acquired the leading Croatian pharmaceutical company, Pliva. 
 
We may point out that the world pharmaceutical industry has become more 
and more oligopolistic. In that context, one may entirely refer to 
Knickerbrocker's (1973) theory of oligopolistic reaction, saying that 
“oligopolistic companies, as those minimizing taking risks in avoidance of 
destroying effects of competition, follow each other to new markets to protect 
their own interests. It is significant that the action of one player creates the 
reaction of other competitors, an action creates a reaction and so the story of 
the oligopolization is going on”. We may conclude that Knickerbrocker's theory 
perfectly illustrates and explains the process of consolidation of the world 
pharmaceutical industry. 
 
Alliancing processes are continuing to speed up as pharmaceutical 
companies try to follow their competitors' strategies of M&A (Mergers and 
Acquisitions) in an endeavour to maintain their strategic global market position 
and long-term competitiveness. Recent acquisitions and alliancing of several 
pharmaceutical companies performed in 2006 just acknowledge our conclusions 
of the intensive consolidation and oligopolization of the world pharmaceutical 
industry.  
 
Table 5. Overview of the latest pharmaceutical alliances in 2006 
 
Target -taken-over company Acquirer Creating of synergies 
Schering AG, Germany Bayer, Germany R&D, markets, marketing & sales 
Hemofarm, Serbia Stada, Germany markets, products, sales 
Serono, Switzerland Merck KGaA, Germany R&D, markets, marketing & sales 
Schwarz Pharma, Germany UCB, Belgium R&D, products, markets, marketing & sales 
Altana Pharma, Germany Nycomed, Denmark R&D, markets, products, marketing & sales 
Hospira, USA Mayne Pharma, Australia products, markets, sales 
Pliva, Croatia Barr Pharmaceuticals, USA markets, products, R&D (biogenerics), sales 
Kos Pharmaceuticals, USA Abbott, USA R&D, products 
 
Source:  own estimation, according to companies’ official data. 
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It is thus evident that some pharmaceutical companies are not able to 
satisfy long-term and ever-changing market needs and customers' expectations, 
to invest heavily into R&D and marketing and sales activities in the endeavour 
to bring new products to the global markets and materialize them properly. We 
can clearly see that this process enables the pharmaceutical companies new 
development circles and their long-term development and growth. We may 
underline that the alliancing of partners for the sake of maintaining long-term 
growth and competitiveness is today one of the most usable strategies in the 
world pharmaceutical industry. We argue that pharmaceutical companies make 
alliances in endeavours to create common synergies and to better exploit their 
common assets, knowledge, product life cycle and, moreover, to improve their 
strategic market positions. Thus, the most important and strategic activities of 
creating common strategies for the pharmaceutical companies are:  
 
• products, to gain market shares and to drive the sales growth, 
• research and development (R&D), to create new products,  
• markets, to create geographic and market expansion, 
• marketing and sales activities, to compete on the global markets, 
• financials, to create common cost reduction synergies and investment 
capabilities.  
 
Due to the complexity of the world pharmaceutical industry, we may stress 
that pharmaceutical companies tend to form alliances and even compete at the 
same time. They can cooperate on some particular projects (for example, R&D), 
however, they compete strongly for the particular market shares.  
 
Svetličič (1996), thus, properly emphasized that “alliancing of companies 
has become attractive due to: 
 
• rising costs of the innovation and entrance to new markets, 
• reinforcing of cost reduction competition, 
• pressure to enlarged gaining of synergistic technologies and 
economies of scale and synergy with help of alliancing and 
acquisitions, 
• endeavours to protect existing market shares and to conquer new ones, 
• rising need to shrink time, needed from an innovation to enter the 
market with a product”. 
 
Pharmaceutical companies tend to internationalize and globalize their 
business activities sooner, as in the past, due to market liberalization, increased 
competitiveness and the need to reach considerable economies of scale.    
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According to that, Svetličič (1996) stipulates that “modern ways of 
internationalization with an aid of network formation and strategic alliancing 
enable an internationalization without a growth of the companies. Today, 
companies decide for the internationalization and alliancing to: 
 
• be closer to customers, 
• increase an effectiveness, 
• gain better access to technologies and knowledge (know-how), 
• to protect from competitors (strategic reasons)”. 
 
The pharmaceutical industry in Eastern Europe has been faced with the 
intensive globalization process as well. In our research, we found out that the 
majority of the pharmaceutical industry in the region has lost its strategic 
sovereignty. The majority of the leading and most important Eastern European 
pharmaceutical companies (Lek from Slovenia, Pliva from Croatia, Hemofarm 
from Serbia, and a great majority of the Polish, Czech, Slovak, Romanian and 
Bulgarian pharmaceutical companies) have been taken-over by international or 
multinational pharmaceutical companies in the intensive globalization and the 
driving merger & acquisition processes. These processes have definitively 
changed the strategic perspective and position of the pharmaceutical industry in 
Eastern Europe. Thus, it has lost its strategic stand-alone position and ability to 
grow and compete in the international markets and benefit on the globalization 
opportunities as well. A further operational rationalization and restructuring of 
these taken-over companies are realistically expected with some strategic and 
managerial implications to be implemented subsequently, including some 
unfavourable ones (reducing the number of business functions and number of 
employees, rationalization and restructuring) which will further change the 
outlook and strategic perspective of the pharmaceutical industry in Eastern 
Europe.  
 
4. MANAGEMENT IN THE PHARMACEUTICAL INDUSTRY  
 
World guru of management, Peter Drucker, who has especially emphasized 
the core importance of strategic marketing management for a successful, long-
term highly competitive business performance of companies, has once said 
about globalization and globalization management: “In the years to come, there 
will be two types of top managers: those who would be able to think globally 
with strong strategic marketing management commitment and those 
jobless”. Strategic marketing management with an emphasized global way of 
thinking, performance and management thus enables companies to put 
customers into the centre of all their business activities and integrally focus all 
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business activities to a common and final goal – to be successful in satisfying 
customers’ needs and to be better than the competitors. It is worth underlining 
as well the importance of innovative management and management of changes. 
As Bartlett and Ghosal (1989) emphasized, “successful companies of today and 
tomorrow will be those ones who would be able at the same time to satisfy local 
needs, increase global effectiveness and strive for constant innovativeness and 
concomitant global learning”. 
 
Companies of today, and moreover, companies of tomorrow make business 
as they would have been on the battle fields, with fast changing competition, 
quick technological development, new and changing regulatory issues in the 
conditions of changing world trade policies, and with predominantly less and 
less loyal customers. We need to take into consideration that today, and even 
more tomorrow, customers have had in each product category numerous offers 
of various products and different, ever-changing demands to various 
combinations of products and services and to various prices. On such a rich 
variety of offers, customers will definitively decide for that product or service 
which would be able to optimally fulfill their individual needs and expectations. 
Thus, it comes as no surprise to us that successful companies know how to 
satisfy their focused customers. In these companies, strategic management with 
a strong market orientation represents a business philosophy of the whole 
company, instead of being just a separate function. This perfectly underlines 
Peter Drucker (1973), when saying “strategic marketing management is so 
important that it cannot be a stand-alone function. If we look upon it from the 
point of final result, that means from the point of final customer, marketing 
represents whole business, whole business performance. Care for a strategic 
marketing must go through all company structures. Business success is not 
dependent upon a producer, but upon a customer. Thus whole and thoroughly a 
strategic marketing management concept should be the most important one in a 
company, and must prevail over innovativeness, organization, financial 
resources, physical sources, productivity, social responsibility and demand for 
a profit making”. Strategic marketing management is especially important in 
the pharmaceutical industry as pharmaceutical companies tend to be market 
oriented and proactive by emphasizing the advantage of their pharmaceutical 
products, as they try to communicate within regulatory allowed frameworks, 
they tend to build strong brand names (trade marks) and create long-term 
loyalty to final customers. Thus, we may argue that strategic management with 
a strong market orientation is, by all means, the most important top business 
function in the global pharmaceutical industry.  
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The concept of strategic management with an emphasized market 
orientation and a certain focus clearly designates one company's business 
philosophy, respectively. We may entirely agree with Corstjens' (1991) 
conclusions that “sector of the pharmaceutical industry, despite being very 
specific in all aspects, is an ideal case, how the practice and usage of strategic 
marketing management concept directly relates to a very successful business 
performance of this industrial sector”.  
 
According to our estimation, strategic management with a strong market 
orientation focus is, by no doubt, the most important function of a long-term 
successful company's business performance. Changes of today’s world, even yet 
of tomorrow, are so fast and profound that it is difficult to follow them entirely. 
This is especially significant for the world pharmaceutical industry. However, 
changes represent new challenges as well and create new business 
opportunities. Thus, it is important to react and act quickly and to be proactive. 
The urgency of a quick adaptation is not just the strategy for smaller companies 
and countries but is a valid strategy of a victorious survival for bigger systems, 
too, as changes in the world economy and globalization are fast and 
tremendous. It is why we may argue that a strategic management with a 
dedicated market orientation is the decisive factor of strategic business success 
in a highly globalized and ever-changing world market place.  
 
We may say that the world pharmaceutical companies perform their 
business activities in a very turbulent environment which requires constant 
adaptation to changes and quick final action decisions. We are of the opinion 
that pharmaceutical companies which want to be globally leading ones and 
successful business performers in the future need to primarily think entirely and 
differently about customers, markets, competitiveness, competitors, and strategy 
with relation to structure to reach the planned goals. They need to especially 
bear in mind that the needs of tomorrow’s customers are different from the 
needs of today’s customers and they do change fast and tremendously in 
relation to the elements and facts which are important to the pharmaceutical 
industry itself. In that relation, we foresee the decisive role of strategic 
management with a strong market orientation as crucial and most important as 
well for the pharmaceutical companies to be successful performers in the future 
and even more globalized world.  
 
5. CONCLUSIONS AND MANAGERIAL IMPLICATIONS 
 
The world pharmaceutical industry has been changing profoundly in the 
last decade. Intensive processes of concentration and consolidation have been 
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continuing in all three sectors of the world pharmaceutical industry. The fast 
globalization process definitively influences and reinforces the consolidation of 
the world pharmaceutical industry. Increased competitiveness and the amended 
structure of competitors impact the strategic orientation of the world 
pharmaceutical companies. Alliancing, in forms of mergers and acquisitions, 
prevail more and more as a strategic orientation for the world pharmaceutical 
companies.  
 
By alliancing, they tend to create strategic synergies in endeavours to be 
globally and long-term successful, competitive and capable to continue with the 
needed development circles. We may estimate that further alliancing processes 
in the world pharmaceutical industry are realistically expected. In that relation, 
Hamel and Prahalad (1994) stipulated that “a competition for tomorrow will be 
predominantly among allied companies, that means among a coalition of the 
companies and stand-alone companies. Coalition of companies will be needed 
for several reasons; it is obvious that not a single company has had enough 
needed resources to benefit from the potential of new products, and needed 
knowledge and skills to change its vision into reality; companies need to make 
the partner alliancing to lower risks, to increase business effectiveness and 
competitiveness. Companies cooperate and compete at the same time. These 
two phases are interchanged, predominantly as future becomes for all much 
more complex”. According to our research survey, we may argue that alliancing 
processes in the world pharmaceutical industry are to continue to form even 
bigger pharmaceutical concerns and conglomerates and to even speed up further 
the oligopolization of the global pharmaceutical industry. 
 
However, we may argue as well that a fast consolidation of the world 
pharmaceutical industry is a market driven and conditioned process by 
significant strategic management issues, like a lack of new products, intensive 
competitiveness, fast globalization, increased global marketing and sales 
activities, changed structure of competitors, fight for global market shares and 
customers' loyalty. Thus, we may again properly refer to Hamel and Prahalad 
(1994) who exclusively put the strategic importance of customers to the highest 
strategic priority of a company by saying that “a company that wants to be 
successful even tomorrow and wants to make profits on tomorrow’s markets, 
must build up competitive advantages which will bring higher relevant value for 
tomorrow’s customers. If a company wants to be a leader, it must be capable to 
re-inovate its industrial segment and re-check its main strategies. A company 
must predominantly become different. If a company wants to be a leader in the 
future, it needs to learn to think differently primarily on four issues: customers, 
meaning of competitiveness, strategy and organizational structure. There is no 
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company able to find the tomorrow day first if it waits and monitors today's 
customers’ needs. Companies which create a future are those ones which 
constantly search for ways to use their competitive advantages in the new 
manner, in the new context and goal, to satisfy future needs of the customers. If 
a company is not able to create future markets and ways to satisfy future needs 
of customers, it will find itself on the magically spilled treadmill, hopelessly 
trying to catch future competitors with falling profits of past performances”. 
 
This is why we emphasize that advanced strategic management with a 
strong market orientation focus should be the most important strategic priority 
of a company that wants to be a successful business performer, to maintain its 
long-term sustainable growth, competitiveness and assure its long-term 
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Svjetska farmaceutska industrija uvelike se promijenila u posljednjem desetljeću. 
Intenzivna globalizacija, povećana konkurencija i borba za udjel na globalnom tržištu 
stvorili su nove izazove za farmaceutske kompanije. Ubrzana globalizacija definitivno 
je djelovala na konsolidaciju svjetske farmaceutske industrije. Stoga sklapanje 
savezništva u obliku pripajanja i akvizicije sve više i više postaje temeljnom strateškom 
orijentacijom svjetskih farmaceutskih kompanija. Spajanjem one žele stvoriti stratešku 
sinergiju kako bi postale uspješnije, konkurentnije i sposobne za nove cikluse 
istraživanja i razvoja. Farmaceutsku industriju u Istočnoj Europi u većini su preuzele 
multinacionalne kompanije, čime su se stvorili novi menadžerski izazovi. Može se 
predvidjeti da će intenzivni procesi povezivanja u svjetskoj farmaceutskoj industriji 
stvoriti još i veće farmaceutske koncerne i ubrzati stvaranje oligopola na globalnoj 
razini. Može se zaključiti da će strateški menadžment, s izrazitom tržišnom 
orijentacijom, odigrati važnu ulogu i biti prioritetna funkcija u budućoj globalizaciji i 
konsolidacijskim procesima u svjetskoj farmaceutskoj industriji. 
 
